In clinical trials
Hormones & metabolism
Efpeglenatide
Evidence
Clinical trials
Class
Long-acting GLP-1 receptor agonist
KEY TAKEAWAY
Efpeglenatide is a once-weekly GLP-1 receptor agonist based on exendin-4. Efpeglenatide is not FDA-approved and has been tested in clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting GLP-1 receptor agonist
Being studied for
Studied in type 2 diabetes and obesity
Key fact
Efpeglenatide is not FDA-approved and has been tested in clinical trials.
Route
Weekly subcutaneous injection in trials
Evidence strength
Clinical trials
Efpeglenatide is a once-weekly GLP-1 receptor agonist based on exendin-4.
It activates GLP-1 receptors, which raises insulin release when blood sugar is high, slows stomach emptying and reduces appetite.
Efpeglenatide is not FDA-approved and has been tested in clinical trials.
Studied in type 2 diabetes and obesity.
Nausea, vomiting and diarrhea were the most common effects in trials.
Efpeglenatide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.